Home › Lilly And AstraZeneca Expand Immuno-Oncology Research Collaboration With New Combinations
 

Keywords :   


Lilly And AstraZeneca Expand Immuno-Oncology Research Collaboration With New Combinations

2015-10-26 04:26:54| drugdiscoveryonline News Articles

Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE:AZN) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.

Tags: research expand collaboration combinations

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
09.06Eastern North Pacific Tropical Weather Outlook
09.06Atlantic Tropical Weather Outlook
09.06Weekly Recap: Kimberly-Clark to Exit Nigeria, Ahlstrom Completes Brazilian Investment & More
09.06Tories promise 730m to end 'sick note culture'
09.06Eastern North Pacific Tropical Weather Outlook
09.06Atlantic Tropical Weather Outlook
09.06Price hikes and boycotts: Is trouble brewing at Starbucks?
09.06Eastern North Pacific Tropical Weather Outlook
More »